The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: Role in adhesion, invasion, and homing

Blood

Volumn 91, Issue 2, 1998, Pages 406-418

  Skorski, Tomasz ^a,c   Nieborowska Skorska, Malgorzata ^d   Wlodarski, Pawel ^d   Wasik, Mariusz ^d   Trotta, Rossana ^d   Kanakaraj, Palanisamy ^d   Salomoni, Paolo ^d   Antonyak, Mark ^d   Martinez, Robert ^d   Majewski, Miroslaw ^d   Wong, Albert ^d   Perussia, Bice ^d   Calabretta, Bruno ^b  

^a Elsa U Pardee Foundation

^b AMERICAN CANCER SOCIETY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; RAS PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL INVASION; CELL ONCOGENE; CONTROLLED STUDY; LEUKEMOGENESIS; LYMPHOCYTE HOMING; LYMPHOCYTE TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

EID: 0031982854     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.2.406     Document Type: Article

References (70)

1. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315:550, 1985
2. Clark SS, McLaughlin J, Timmonis M, Pendergast AM, BenNeriah Y, Dow L, Rovera G, Smith SD, Witte ON: Expression of a distinctive bcr-abl oncogene in Phl-positive acute lymphoblastic leukemia (ALL). Science 239:775, 1988
3. bcr/abl gene of the Philadelphia chromosome. Science 247:824, 1990
4. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J: Acute leukemia in bcr/abl transgenic mice. Nature 344:351, 1990
5. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253:562, 1991
6. Dhut S, Champlin T, Young BD: BCR/ABL and ABL proteins: Biochemical characterization and localization. Leukemia 4:745, 1990
7. Goga A, McLaughlin J, Afar DEH, Saffran DC, Witte ON: Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82:981, 1995
8. Cortez D, Kadlec L, Pendergast AM: Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 15:5531, 1995
9. Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL: Differential complementation of Bcr-Abl point mutants with c-Myc. Science 264:424, 1994
10. Sanchez-Garcia I, Grutz G: Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 92:5287, 1995
11. Sirard C, Laneuville P, Dick JE: Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic MO7e cells by an autocrine mechanism. Blood 83:1575, 1994
12. Gordon MY, Dowding CR, Riley GP, Goldman JH, Greaves MF: Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myeloid leukemia. Nature 328:342, 1987
13. Verfaillie CM, McCarthy JB, McGlave PB: Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. J Clin Invest 90:1232, 1992
14. Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR, Witte ON: BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 11:1785, 1991
15. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON: BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66:161, 1991
16. Pendergast AM, Gishizky ML, Havlik MH, Witte ON: SH1 domain autophosphorylation of p210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol 13:1728, 1993
17. Reuther GW, Fu H, Cripe LD, Collier RJ, Pendergast AM: Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family. Science 266:129, 1994
18. Oda T, Tamura T, Griffin JD, Druker BJ: The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. Leukemia 9:295, 1995
19. BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood 86:3897, 1995
20. Skorski T, Kanakaraj P, De-Hui K, Nieborowska-Skorska M, Canaani E, Zon G, Perussia B, Calabretta B: Negative regulation of p120GAP GTPase promoting activity by p210Bcr-Abl: Implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med 179:1855, 1994
21. Sawyers CL, McLaughlin J, Witte ON: Genetic requirement for RAS in the transformation of fibroblasts and hematopoietic cells by the BCR/ABL oncogene. J Exp Med 181:307, 1995
22. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B: Phosphatidyl-inositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86:726, 1995
23. Skorski T, Nieborowska-Skorska M, Szczylik C, Kanakaraj P, Perrotti D, Zon G, Gewirtz AM, Perussia B, Calabretta B: c-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res 55:2275, 1995
24. Sawyers CL, Callahan W, Witte ON: Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70:901, 1992
25. Afar DEH, McLaughlin J, Sherr CJ, Witte ON, Roussel MF: Signaling by ABL oncogenes through cyclin D1 Proc Natl Acad Sci USA 92:9540, 1995
26. Mandanas RA, Boswell HS, Lu L, Leibowitz D: BCR/ABL confers growth factor independence upon a myeloid cell line. Leukemia 6:769, 1992
27. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038, 1994
28. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr/abl oncogene products. Science 247:1079, 1990
29. Van Etten RA, Jackson P, Baltimore D: The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58:669, 1989
30. Valtieri M, Tweardy DJ, Caracciolo D, Johnson K, Mavilio F, Airman S, Santoli D, Rovera G: Cytokine-dependent granulocytic differentiation. Regulation of proliferative and differentiative responses in a murine progenitor cell line. J Immunol 138:3829, 1987
31. bcr/abl tyrosine kinase. Proc Natl Acad Sci USA 93:13137, 1996
32. Thomas SM, DeMarco M, D'Arcangelo G, Hagelogua S, Brugge JS: Ras is essential for nerve growth factor-and phorbol ester-induced tyrosine phosphorylation of MAP kinases. Cell 68:1031, 1992
33. Hibi T, Lin A, Smeal T, Minden A, Karin M: Identification of an oncoprotein-and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7:2135, 1993
34. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987
35. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B: Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood 88:1005, 1996
36. Habets GGM, Schottes EHM, Zuydgeest D, van der Kammen RA, Starn JC, Berns A, Collard JG: Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. Cell 77:537, 1994
37. Braselman S, McCormick F: BCR and RAF form a complex in vivo via 14-3-3 proteins. EMBO J 14:4839, 1995
38. Gishizki ML, Witte ON: Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 256:836, 1992
39. 1 leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 92:194, 1993
40. Van Etten RA, Debnaith J, Zhou H, Casasnovas JM: Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro. Oncogene 10:1977, 1995
41. Kaplan KB, Bibbins KB, Swedlow JR, Arnaud M, Morgan DO, Varmus HE: Association of the amino-terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. EMBO J 13:4745, 1994
42. Weng Z, Rickles RJ, Feng S, Richard S, Shaw AS, Schreiber SL, Brugge JS: Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions. Mol Cell Biol 15:5627, 1995
43. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T: SH2 and SH3 domains: Elements that control-interactions of cytoplasmic signalling proteins. Science 252:668, 1991
44. Liu X, Marengere LEM, Koch CA, Pawson T: The v-src SH3 domain binds phosphatidylinositol 3′-kinase. Mol Cell Biol 13:5225, 1993
45. Pleiman CM, Hertz WM, Cambier JC: Activation of phosphatidyl-inositol-3′ kinase by src-family kinase SH3 binding to the p85 subunit. Science 263:1609, 1994
46. Bergold PJ, Blumenthal JA, Andrea ED, Snyder HW, Lederman L, Silverstone A, Nguyen H, Besmer P: Nucleic acid sequence and onco-genic properties of the HZ2 Feline sarcoma virus v-abl insert. J Virol 61:1193, 1987
47. Goga A, McLaughlin J, Pendergast AM, Parmar K, Muller A, Rosenberg N, Witte ON: Oncogenic activation of c-ABL by mutation within its last exon. Mol Cell Biol 13:4967, 1993
48. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E: Alternative splicing of RNAs transcribed from the human abl gene and from bcr-abl fused gene. Cell 47:277, 1986
49. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T: Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13:764, 1994
50. Tauchi T, Boswell HS, Leibowitz D, Broxmeyer HE: Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to Ras activation pathway. J Exp Med 179:167, 1994
51. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley L: Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 11:1107, 1991
52. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL: The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 92:11746, 1995
53. Kabarowski JHS, Alien PB, Wiedermann LM: A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 13:5887, 1994
54. Carlesso N, Frank DA, Griffin JD: Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 183:811, 1995
55. Hynes RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69:11, 1992
56. Cicchetti P, Mayer BJ, Thiel G, Baltimore D: Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. Science 257:803, 1992
57. Shi Y, Alin K, Goff SP: Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev 9:2583, 1995
58. Dai Z, Pendergast AM: Abl-2, a novel SH3-containing protein, interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev 9:2569, 1995
59. Zhu J, Shore SK: c-Abl tyrosine kinase activity is regulated by association with a novel SH3-domain-binding protein. Mol Cell Biol 16:7054, 1996
60. Afar DEH, Han L, McLaughlin J, Wong S, Dhaka A, Parmar K, Rosenberg N, Witte ON, Colicelli J: Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RlN1. Immunity 6:773, 1997
61. Wen S-T, VanEtten RA: The product of the PAG gene is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev (in press)
62. Anderson SM, Mladenovic JM: The BCR/ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion. Blood 87:238, 1996
63. Drubin DG, Mulholland J, Zhu Z, Botstein D: Homology of a yeast actin-binding protein to signal transduction proteins and myosin-1. Nature 343:288, 1990
64. Musacchio A, Gibson T, Lehto VP, Saraste M: SH3-An abundant protein domain in search of a function. FEBS Lett 307:55, 1992
65. Pawson T, Gish G: SH2 and SH3 domains: From structure to function. Cell 71:359, 1992
66. Schlaepfer DD, Hanks SK, Hunter T, van der Geer P: Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature 372:786, 1994
67. bcr/abl. Oncogene 11:1149, 1995
68. Clark EA, Brugge JS: Integrins and signal transduction pathways: The road taken. Science 268:233, 1995
69. Wary KK, Mainiero F, Isakoff SJ, Marcantonio EE, Giancotti FG: The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Cell 87:733, 1996
70. Erpel T, Superti-Furga G, Courtneidge SA: Mutational analysis of the Src SH3 domain: The same residues of the ligand binding surface are important for intra-and intermolecular interactions. EMBO J 14:963, 1995